伴FLT3-ITD、NPM1与DNMT3A共突变急性髓系白血病的移植选择与时机优化
该回顾性研究分析了2016至2023年2541例接受二代测序的AML患者,其中113例携带FLT3-ITD、NPM1与DNMT3A三重突变。与持续化疗相比,异基因造血干细胞移植与更优的2年总生存相关(62.2% vs 17.8%,p<0.001),但首次化疗后达复合完全缓解且DNMT3A可测量残留病阴性或流式MRD阴性的患者未见额外获益。移植前首次化疗后达复合完全缓解者移植后2年总生存、无白血病生存及非复发死亡率均更优。
要点
- 三重突变AML中,异基因移植较持续化疗改善2年总生存(62.2% vs 17.8%)。
- 首次化疗后DNMT3A MRD阴性或流式MRD阴性的复合完全缓解者,移植未见额外获益。
- 移植前首次化疗后达复合完全缓解者,移植后2年总生存与无白血病生存更优。
核心结论
- 对于伴FLT3-ITD、NPM1与DNMT3A共突变的AML患者,异基因造血干细胞移植较持续化疗与更优的2年总生存相关。
- 首次化疗后达复合完全缓解且DNMT3A MRD阴性或流式MRD阴性的患者,异基因移植未见明确额外获益。
研究设计与样本
- 回顾性分析2016至2023年接受二代测序的2541例AML患者。
- 其中113例携带FLT3-ITD、NPM1与DNMT3A三重突变且有治疗结局,79例接受异基因造血干细胞移植,34例接受持续化疗。
主要发现
- 异基因移植组2年总生存为62.2%,持续化疗组为17.8%(p<0.001)。
- 移植前首次化疗后达复合完全缓解者,移植后2年总生存为71.9% vs 44.1%(p=0.028)。
- 移植前首次化疗后达复合完全缓解者,移植后2年无白血病生存为65.4% vs 40.2%(p=0.029)。
- 移植前首次化疗后达复合完全缓解者,移植后2年非复发死亡率为17.4% vs 40.4%(p=0.037)。
- 含维奈克拉的强化化疗(88.2%)或非强化化疗(63.6%)的复合完全缓解率高于单纯化疗(p=0.001)。
关键数值与推荐
- 复合完全缓解(CRc)率:含维奈克拉强化化疗88.2%,含维奈克拉非强化化疗63.6%,单纯化疗较低(p=0.001)。
- 移植前首次化疗后达CRc者移植后2年OS 71.9% vs 44.1%(p=0.028)、LFS 65.4% vs 40.2%(p=0.029)、NRM 17.4% vs 40.4%(p=0.037)。
临床怎么用
- 对三重突变AML,异基因移植可作为改善长期生存的巩固策略,尤其适用于首次化疗后未达深度MRD阴性缓解者。
- 首次化疗后达CRc且DNMT3A MRD阴性或流式MRD阴性者,可个体化评估移植的必要性与时机。
- 诱导/巩固化疗可考虑含维奈克拉方案以提高复合完全缓解率。
局限性
- 回顾性设计,样本量有限(三重突变仅113例),可能存在选择偏倚。
- 移植与化疗组间基线特征未在摘要中完整报告,混杂因素可能影响比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukaemia (AML) patients with concurrent FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD), nucleophosmin 1 (NPM1) and DNA methyltransferase 3 alpha (DNMT3A) mutations exhibit heterogeneous treatment outcomes. To identify optimal strategies for this subset, we retrospectively analysed 2541 AML patients with next-generation sequencing from 2016 to 2023. Among them, 113 harboured triple mutations and had treatment outcomes: 79 received allogeneic haematopoietic stem cell transplantation (allo-HSCT), and 34 underwent continuous chemotherapy (CMT). Compared with CMT, allo-HSCT was associated with superior 2-year overall survival (OS) (62.2% vs. 17.8%, p < 0.001). However, no clear additional benefit from allo-HSCT was observed in patients who achieved composite complete remission (CRc) with DNMT3A measurable residual disease (MRD) negativity or complete remission with negative multiparameter flow cytometry MRD after the first cycle of CMT (CMT1st). Among patients who underwent allo-HSCT, those in CRc after CMT1st had significantly improved post-transplant 2-year OS (71.9% vs. 44.1%, p = 0.028), leukaemia-free survival (65.4% vs. 40.2%, p = 0.029) and non-relapse mortality (17.4% vs. 40.4%, p = 0.037). CRc rates were higher with venetoclax-based intensive (88.2%) or non-intensive (63.6%) CMT than with CMT alone (p = 0.001). In conclusion, this study offers a potential treatment paradigm for AML patients with co-occurring FLT3-ITD, NPM1 and DNMT3A mutations.
引用
- Li R, Yao Y, Yang D, et al. Optimizing treatment selection and timing of allogeneic haematopoietic stem cell transplantation in acute myeloid leukaemia with concurrent feline McDonough sarcoma (FMS)-like tyrosine kinase 3 internal tandem duplication, nucleophosmin 1 and deoxyribonucleic acid (DNA) methyltransferase 3 alpha mutations. Br J Haematol. 2026. PMID: 42230972. doi:10.1111/bjh.70593
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。